Pharmacokinetics and toxicity of intravesical TMX-101: A preclinical study in pigs

BJU International

Volumn 108, Issue 7, 2011, Pages 1210-1214

  Arentsen, Harm C ^a   Hulsbergen Van De Kaa, Christina A ^a   Jansen, Cornelius F J ^a   Maj, Roberto ^b   Leoni, Lorenzo M ^b   Oosterwijk, Egbert ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Telormedix SA   (Switzerland)

Author keywords

bladder neoplasms; immunotherapy; intravesical therapy; pigs; TLR 7; TMX 101

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CREATININE; IMIQUIMOD; INTERLEUKIN 6; LACTIC ACID; POLOXAMER; TMX 101; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLOOD CELL COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG INSTILLATION; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; FEMALE; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LOOSE FECES; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; SWINE; THROMBOCYTE COUNT; URINALYSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AMINOQUINOLINES; ANIMALS; SWINE;

EID: 80052810159     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10055.x     Document Type: Article

References (12)

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J,. European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14
2. Witjes JA, Palou J, Soloway M, et al,. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 2008; 7: 667-74
3. Hemmi H, Kaisho T, Takeuchi O, et al,. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200 (Pubitemid 34141451)
4. Tyring S, Conant M, Marini M, Van der Meijden W, Washenik K,. Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol 2002; 41: 810-6 (Pubitemid 35422853)
5. Smith EB, Schwartz M, Kawamoto H, et al,. Antitumor effects of Imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol 2007; 177: 2347-51 (Pubitemid 46726385)
6. Liu H, Schwartz MJ, Hwang DH, Scherr DS,. Tumor growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma. BJU Int 2008; 101: 894-901 (Pubitemid 351347734)
7. Sylvester FJ, Van der Meijden AP, Lamm DL,. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70
8. Malmström PU, Sylvester RJ, Crawford ED, et al,. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical Mitomycin C versus Bacillus Calmettte-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-56
9. Schön MP, Schön M,. Imiquimod: mode of action. Br J Dermatol 2007; 157: 8-13 (Pubitemid 350179622)
10. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M,. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33 (Pubitemid 38580549)
11. Witt PL, Ritch PS, Reding D, et al,. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993; 53: 5176-80 (Pubitemid 23333384)
12. Hayashi T, Crain B, Corr M, et al,. Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol 2010; 17: 483-91